Global /China /Healthcare /Drug Manufacturers - General /688321

Shenzhen Chipscreen Biosciences Co., Ltd.

688321

• SSE: 688321 • Delayed

31.32CNY 5.4%

4.63 USD

As of 16 June 2026, Shenzhen Chipscreen Biosciences Co., Ltd. has a market cap of $1.95B USD, ranking #7191 globally and #1771 in China. It ranks #578 in the Healthcare sector, and #227 in the Drug Manufacturers - General industry.

Global Rank

7191

Country Rank

1771

Sector Rank

578

Industry Rank

227

Key Stats

Market Cap

$1.95BUSD

13.17B CNY

Enterprise Value

$2.08BUSD

14.07B CNY

Revenue (TTM)

$134.48MUSD

910.06M CNY

EBITDA (TTM)

$22.62MUSD

153.07M CNY

Net Income (TTM)

$7.53MUSD

50.96M CNY

EBITDA Margin

17%

Profit Margin

5.6%

PE Ratio

237.8

PS Ratio

14.5

PB Ratio

8.1

EV/EBITDA

90.6

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Xian-Ping Lu open_in_new

Employees

1,002

Founded

2001

Website

chipscreen.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
5.4%	3.8%	4.7%	-3.9%	7.9%	7.5%	85%	24%	-13%

News

Markets

Exchange	Ticker	Price	Quotes
Shanghai Stock Exchange (SSE / SHA) MIC: XSHG PRIMARY	688321 深圳微芯生物科技股份有限公司 Class A ISIN: CNE100003LW0 Shares Out.: Shares Outstanding: 442.403M¹ Shares Float: 273.549M² TV: TradingView: SSE: 688321 SA: Stock Analysis: SHA: 688321 YF: Yahoo Finance: 688321.SS GF: Google Finance: SHA: 688321 BA: Barron's: 688321 MS: Morningstar: XSHG: 688321	31.32 CNY	TV: TradingView: SSE: 688321 SA: Stock Analysis: SHA: 688321 YF: Yahoo Finance: 688321.SS GF: Google Finance: SHA: 688321 BA: Barron's: 688321 MS: Morningstar: XSHG: 688321

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Shenzhen Chipscreen Biosciences Co., Ltd.

Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research and development of original small molecule drugs. The company develops Chidamide, a subtype-selective histone deacetylase inhibitor for the treatment of peripheral T-cell lymphoma and advanced hormone receptor-positive breast cancer; Chiglitazar Sodium, a PPAR pan-agonist for the treatment of metabolic diseases; and Chiauranib, a triple-pathway tumor-targeting inhibitor. It is also developing CS23546, a small-molecule PD-L1 inhibitor; CS231295, a brain-penetrant Aurora B selective inhibitor; CS32582, a highly selective small-molecule allosteric inhibitor of tyrosine kinase 2; CS12088, a hepatitis B nucleocapsid assembly modulator; and CS12192 a highly selective JAK3 kinase inhibitor. The company was founded in 2001 and is headquartered in Shenzhen, China.

Similar Companies

Industry: Drug Manufacturers - General (China)

Name	Market Cap (USD) diff.	PE	Country
Jiangsu Hengrui Pharmaceuticals Co.,Ltd SSE: 600276	$53.92B 364.89B CNY 3K%	44.9	China
WuXi AppTec Co., Ltd. SSE: 603259	$49.7B 336.36B CNY 2K%	17.2	China
Hansoh Pharmaceutical Group Company Ltd. SHEK: 3692	$28.52B 223.48B HKD 1K%	35.7	China
Innovent Biologics, Inc. SHEK: 1801	$18.8B 147.32B HKD 866%	162.3	China
Sichuan Biokin Pharmaceutical Co.,Ltd. SSE: 688506	$16.53B 111.89B CNY 750%	-	China
Akeso, Inc. SHEK: 9926	$16.01B 125.46B HKD 723%	-	China

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 39K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 28K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 18K%	97.4	United States
Roche Holding AG SIX: RO	$320.51B 256.25B CHF 16K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.14B 215.59B GBP 15K%	27.6	United Kingdom
Merck & Co., Inc. NYSE: MRK	$274.03B 14K%	15.1	United States

chevron_leftBack